Group
Hedgehog Pathway Inhibitors
Group Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | Hedgehog Pathway Inhibitors |
| Mechanism of Action | Smoothened receptor antagonist |
| Drugs in group | Sonidegib· Vismodegib |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Radiosensitizing in HH-dependent tumors (reverses GLI1-driven repair/stemness/repopulation), partly p53-dependent (Teichman et al., PLoS One, 2018; Zhang et al., Frontiers in Cell and Developmental Biology, 2023; Gan et al., Cancer Research, 2014). Where GLI signaling also supports normal epithelial/stem compartments, a theoretical increase in mucocutaneous adverse events is possible.
The data above refer to patients treated with Hedgehog Pathway Inhibitors as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.